Ceritinib: all 39 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Ceritinib Treatment for Recurrent MeningiomasNot yet recruitingNCT07893197Phase 2
• Using Tumor Models to Determine TreatmentsRecruitingNCT06813079Phase 2
• Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedNCT03737994Phase 2Results posted
• Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTerminatedNCT02587650Phase 2Results posted
• Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung AdenocarcinomaTerminatedNCT02513667Phase 2Results posted
• Ceritinib Rare Indications Study in ALK+ TumorsTerminatedNCT02465528Phase 2Results posted
• LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.CompletedNCT02450903Phase 2Results posted
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to LeptomeningesCompletedNCT02336451Phase 2Results posted
• A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerCompletedNCT02276027Phase 2Results posted
• Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)TerminatedNCT02186821Phase 2Results posted
• LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibCompletedNCT02040870Phase 1/2Results posted
• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibCompletedNCT01828112Phase 3Results posted
• LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerCompletedNCT01828099Phase 3Results posted
• Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)CompletedNCT01742286Phase 1Results posted
• LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung CancerCompletedNCT01685138Phase 2Results posted
• LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and CrizotinibCompletedNCT01685060Phase 2Results posted
• A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma KinaseCompletedNCT01283516Phase 1Results posted
• Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
• Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCActive, not recruitingNCT03611738Phase 1
• Study of Trametinib + Ceritinib in Patients With Unresectable MelanomaCompletedNCT03501368Phase 1
• A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementStatus unknownNCT03399487Phase 2
• Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03087448Phase 1
• Next Generation Personalized Neuroblastoma TherapyTerminatedNCT02780128Phase 1
• Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT02729961Phase 1/2
• Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal MalignanciesTerminatedNCT02638909Phase 2
• Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS MetastasisCompletedNCT02605746Early Phase 1
• Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored StudyActive, not recruitingNCT02584933Phase 4
• A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced TumorsCompletedNCT02422589Phase 1
• Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerActive, not recruitingNCT02393625Phase 1
• A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar CholangiocarcinomaTerminatedNCT02374489Phase 2
• Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem MalignanciesWithdrawnNCT02343679Phase 2
• Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerActive, not recruitingNCT02321501Phase 1
• Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT02299505Phase 1
• Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.CompletedNCT02292550Phase 1
• Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid CancerWithdrawnNCT02289144Phase 2
• An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementCompletedNCT01964157Phase 2
• Effect of Hepatic Impairment on LDK378 PharmacokineticsCompletedNCT01950481Phase 1
• Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung CancerCompletedNCT01772797Phase 1
• Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)CompletedNCT01634763Phase 1

← Ceritinib overview